ライフサイエンスコーパス: immunomodulatory drug

1 hich suggests the novel use of ICOS-Fc as an immunomodulatory drug.

2 exposed to bortezomib, alkylators, and other immunomodulatory drugs.

3 may improve the therapeutic potential of the immunomodulatory drugs.

4 hematopoietic stem cell transplantation and immunomodulatory drugs.

5 NPM1 mutation and predicted the response to immunomodulatory drugs.

6 ous treatment with proteasome inhibitors and immunomodulatory drugs.

7 t is refractory to proteasome inhibitors and immunomodulatory drugs.

8 lation followed by a systemic application of immunomodulatory drugs.

9 or GSPT1] whose ubiquitylation is induced by immunomodulatory drugs.

10 HIV, including use of anti-inflammatory and immunomodulatory drugs.

11 use of interactors of the ICOS:B7h system as immunomodulatory drugs.

12 of thalidomide and member of a new class of immunomodulatory drugs.

13 d its occurrence as a side effect of certain immunomodulatory drugs.

14 argets for the development of new classes of immunomodulatory drugs.

15 ne response against influenza virus using an immunomodulatory drug, AAL-R, provides significant prote

16 Lenalidomide is an immunomodulatory drug active as salvage therapy for chro

17 We hypothesized that the immunomodulatory drug alefacept would result in targeted

18 understanding how rapamycin functions as an immunomodulatory drug and for the development of complem

19 ease refractory to proteasome inhibitors and immunomodulatory drugs and 64% had disease refractory to

20 ts enrolled, all having prior bortezomib and immunomodulatory drugs and a median of 5 prior regimens.

21 Although several immunomodulatory drugs and molecules are available, most

22 With the introduction of novel agents-immunomodulatory drugs and proteasome inhibitors-respons

23 nd clinical studies with thalidomide and the immunomodulatory drugs and their application in differen

24 th >/=2 prior lines of therapy, including an immunomodulatory drug, and patients who had progressed o

25 ents, purine analogs, proteasome inhibitors, immunomodulatory drugs, and mammalian target of rapamyci

26 t regimens containing proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies.

27 The immunomodulatory drugs are a novel, nonteratogenic class

28 Immunomodulatory drugs are active agents in light-chain

29 er, 5-lipoxygenase inhibitors, anti-IgE, and immunomodulatory drugs are also likely to have a place i

30 gests that traditional immunosuppressive and immunomodulatory drugs are certainly effective in polymy

31 sing because of the HIV pandemic and because immunomodulatory drugs are increasingly used to treat au

32 and its novel T cell costimulatory analogs (immunomodulatory drugs) are currently being assessed in

33 ese results warrant further investigation of immunomodulatory drugs as maintenance in high-risk patie

34 Pom-Dex, a doublet immunomodulatory drug-based regimen, is active and well

35 Immunomodulatory drugs bind to cereblon (CRBN) to confer

36 as well as different biological responses to immunomodulatory drugs can be expected to contribute to

37 Evidence suggests that immunomodulatory drugs can directly act on glomerular ep

38 apse are common after surgical resection and immunomodulatory drugs can maintain long-term remission.

39 vated T lymphocytes, and indicate that novel immunomodulatory drugs can serve to inhibit the pathogen

40 In this study, we assessed the ability of an immunomodulatory drug (CC-4047/ACTIMID) to prime a tumor

41 , respectively) could represent an effective immunomodulatory drug combination.

42 s to infection and optimizing strategies for immunomodulatory drug delivery.

43 The class of compounds known as immunomodulatory drugs derived from thalidomide is devel

44 Others have reported that immunomodulatory drugs (e.g., thalidomide and lenalidomi

45 f concept for using tissue explants to study immunomodulatory drugs for asthma.

46 tion of large phase III trials investigating immunomodulatory drugs for atherosclerosis, cardiovascul

47 The role of immunomodulatory drugs for relapses needs further study.

48 To date, no specific immunomodulatory drug has proven efficacy in targeting t

49 The introduction of proteasome inhibitor and immunomodulatory drugs has considerably changed the trea

50 Lenalidomide, a second generation immunomodulatory drug, has shown substantial remitting a

51 Although immunomodulatory drugs have been used extensively in the

52 Thalidomide analogues, the immunomodulatory drugs have increased potency and have d

53 Cereblon (CRBN) mediates immunomodulatory drug (IMiD) action in multiple myeloma

54 The immunomodulatory drug (IMiD) thalidomide and its structu

55 he CoMMpass study, all of which had received immunomodulatory drug (IMiD) therapy.

56 Lenalidomide is an immunomodulatory drug (IMiD) with activity in lymphoid m

57 ory effects of a more potent analog of Thal, immunomodulatory drug (IMiD), on T cells.

58 including a proteasome inhibitor [PI] and an immunomodulatory drug [IMiD]) or were double refractory.

59 Lenalidomide is an immunomodulatory drug (IMiDs) with clinical efficacy in

60 The efficacy of retreatment with immunomodulatory drugs (IMiDs) among patients with multi

61 The introduction of immunomodulatory drugs (IMiDs) and proteasome inhibitors

62 Patients were pretreated with both immunomodulatory drugs (IMiDs) and proteasome inhibitors

63 argets through which thalidomide and related immunomodulatory drugs (IMiDs) exert their antitumor eff

64 Immunomodulatory drugs (IMiDs) lenalidomide and pomalido

65 The immunomodulatory drugs (IMiDs) lenalidomide and pomalido

66 vatives lenalidomide and pomalidomide, these immunomodulatory drugs (IMiDs) recently emerged as effec

67 Thalidomide and lenalidomide are immunomodulatory drugs (IMiDs) that produce high remissi

68 of active agents, proteasome inhibitors and immunomodulatory drugs (IMiDs), resulting in a significa

69 ide teratogenicity and antitumor activity of immunomodulatory drugs (IMiDs).

70 ssociation of LIS with the use of novel oral immunomodulatory drugs (IMiDs; lenalidomide and thalidom

71 tation [HDM-ASCT]) and 2000 (introduction of immunomodulatory drugs [IMiDs]), respectively.

72 mor activity of Thal and its potent analogs (immunomodulatory drugs [IMiDs]).

73 anti-MM activity of Thal and its analogues (immunomodulatory drugs, IMiDs) on MM cells was demonstra

74 a were safe but were not effective as single immunomodulatory drugs in recent-onset type 1 diabetes.

75 eresting template in the quest to design new immunomodulatory drugs in the therapy of immune-related

76 ta, and clinical implications for use of the immunomodulatory drugs in the treatment of myelodysplast

77 IMiDs immunomodulatory drugs, including lenalidomide and pomal

78 s the impairment of immune reconstitution by immunomodulatory drugs leading to life-threatening infec

79 es in human P450-catalysed metabolism of the immunomodulatory drug leflunomide, which likewise underg

80 The immunomodulatory drug lenalidomide is widely used for tr

81 , we studied the clinical significance of an immunomodulatory drug lenalidomide on SGN-40-induced cyt

82 Of clinical relevance, the immunomodulatory drug lenalidomide prevented the inducti

83 The immunomodulatory drug lenalidomide shows therapeutic eff

84 The proteasome inhibitor bortezomib and immunomodulatory drug lenalidomide targeted MM cells in

85 his T-cell defect was demonstrated using the immunomodulatory drug lenalidomide, which completely res

86 atment of both FL cells and T cells with the immunomodulatory drug lenalidomide.

87 T-cell signaling, which was reversed by the immunomodulatory drug lenalidomide.

88 iquitin ligase complex, is the target of the immunomodulatory drugs lenalidomide and pomalidomide.

89 ezomib), mTOR inhibitors (temsirolimus), and immunomodulatory drugs (lenalidomide) have recently been

90 , an aberrant immune response, or the use of immunomodulatory drugs, many of the rheumatic diseases a

91 revious regimens including bortezomib and an immunomodulatory drug, median overall survival was 25.5

92 Most patients could be salvaged with immunomodulatory drugs or radiation.

93 therapy (including proteasome inhibitors and immunomodulatory drugs), or were refractory to both prot

94 o had received treatment with bortezomib, an immunomodulatory drug, or both, or who were receiving a

95 ients in reports published previously-before immunomodulatory drugs-patients who do not achieve parti

96 ight review focuses on the second-generation immunomodulatory drug pomalidomide, which was recently a

97 e safety and therapeutic activity of another immunomodulatory drug, pomalidomide.

98 Our immunomodulatory drug regimen includes induction with an

99 They also suggest that clinical trials of immunomodulatory drugs related to CTLA4 and that are alr

100 thdrawal responded; 7 patients on additional immunomodulatory drugs remain in steroid-free remission

101 vator and self-renewal agonist, and promotes immunomodulatory drug resistance in vitro.

102 The immunomodulatory drugs show exciting erythropoietic acti

103 the teratogenic and antitumor activities of immunomodulatory drugs such as thalidomide, lenalidomide

104 with novel agents, including bortezomib and immunomodulatory drugs, such as lenalidomide.

105 The immunomodulatory drug thalidomide is the treatment of ch

106 These agents include the immunomodulatory drugs thalidomide and lenalidomide, the

107 tive yet have low toxic effects, such as the immunomodulatory drugs thalidomide and lenalidomide.

108 The immunomodulatory drugs, thalidomide and lenalidomide, an

109 EtOH provides an example of an immunomodulatory drug that acts at least in part by modi

110 Lenalidomide is an orally active immunomodulatory drug that has direct antineoplastic act

111 Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but

112 has emerged supporting the role of GA as an immunomodulatory drug that regulates T-cell function.

113 Lenalidomide is an oral immunomodulatory drug that repairs antitumor T-cell func

114 poly (ADP-ribose) polymerase-1 and mTOR and immunomodulatory drugs that are in the early stages of c

115 JAK inhibitors represent a class of immunomodulatory drugs that inhibit signaling by multipl

116 cluding new antiviral agents, symptomatic or immunomodulatory drugs, the re-emergence of natural reme

117 tional (melphalan) and novel (bortezomib and immunomodulatory drugs) therapies.

118 to the most recent proteasome inhibitors and immunomodulatory drugs used, and 103 (97%) were refracto

119 Pomalidomide, a third-generation immunomodulatory drug, was proposed to induce fetal hemo

120 refractory to both proteasome inhibitors and immunomodulatory drugs, were randomly allocated in a 1:1

121 The administration of thalidomide, an immunomodulatory drug with antiangiogenic effects, is li

122 Lenalidomide, an immunomodulatory drug with antineoplastic and antiprolif

123 hree), and status of previous treatment with immunomodulatory drugs (yes or no), and used permuted bl